Filing Details
- Accession Number:
- 0001104659-20-010943
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-05 06:05:41
- Reporting Period:
- 2020-01-31
- Accepted Time:
- 2020-02-05 06:05:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1477845 | Annovis Bio Inc. | ANVS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1290208 | B Michael Hoffman | C/O Annovis Bio, Inc. 1055 Westlakes Drive, Suite 300 Berwyn PA 19312 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-01-31 | 33,333 | $6.00 | 47,619 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 158,730 | $0.00 | 206,349 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 1,137,942 | $0.00 | 1,344,291 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-01-31 | 55,884 | $4.80 | 1,400,175 | No | 4 | C | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A-1 Preferred Stock | Disposition | 2020-01-31 | 222,222 | $0.00 | 158,730 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2020-01-31 | 1,593,118 | $0.00 | 1,137,942 | $0.00 |
| Common Stock | Convertible Note | Disposition | 2020-01-31 | 55,884 | $4.80 | 55,884 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").
- Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price).
Billionaire Hedge Funds
